Qiagen N.V.

Qiagen is provider of Sample to Insight solutions to transform biological materials into valuable molecular insights. Co.'s sample technologies process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software interprets data. Automation solutions unite these together in molecular testing workflows. Co. provides these workflows to four classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). Co. markets its products in more than 130 countries.
  • TickerA2DKCH
  • ISINNL0012169213
  • SectorPharmaceuticals & Biotechnology
  • CountryNetherlands

Analysts

Hugo Solvet

QIAGEN: FDA approval of QIAstat-Dx … all upside | BUY | EUR36.5(+8%)

QIAGEN - BUY | EUR36.5(+8%) FDA approval of QIAstat-Dx … all upside FDA approved QIAstat-Dx Approval slightly earlier than expected Increased confidence in the ability to make the guidance First short term catalyst

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

Hugo Solvet

QIAGEN: Burning questions (roadshow feedback) | BUY | EUR36.5(+11%)

QIAGEN - BUY | EUR36.5(+11%) Burning questions (roadshow feedback) FY19 guidance: make or break? What is driving NGS sales? Reimbursement risk for QIAstat-Dx? Risks that QuantiFERON-TB becomes the next HPV?

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - QIAGEN : Guidance réitérée avec un S2 plus dynamique - NEUTRE, OC 36€ (vs 37€)

Remi Ramadou

QIAGEN NV- Rating report

Qiagen is a provider of innovative sample & assay technologies. The company’s automated systems and consumable products allow customers to transform raw biological amples into valuable molecular insights. Sample technologies are used to isolate DNA, RNA and proteins from any biological sample, such as blood or tissue as well as plants and other samples that contain biological materials. Assay technologies are then used to amplify, enrich and provide results for analysis, such as the DNA of a virus or a mutation of a gene contained in a cancer cell, and these are supported by a portfolio of bio...

Hugo Solvet

QIAGEN: FDA approval of QIAstat-Dx … all upside | BUY | EUR36.5(+8%)

QIAGEN - BUY | EUR36.5(+8%) FDA approval of QIAstat-Dx … all upside FDA approved QIAstat-Dx Approval slightly earlier than expected Increased confidence in the ability to make the guidance First short term catalyst

Hugo Solvet

QIAGEN: Burning questions (roadshow feedback) | BUY | EUR36.5(+11%)

QIAGEN - BUY | EUR36.5(+11%) Burning questions (roadshow feedback) FY19 guidance: make or break? What is driving NGS sales? Reimbursement risk for QIAstat-Dx? Risks that QuantiFERON-TB becomes the next HPV?

Olga Smolentseva ...
  • Thibaut Voglimacci-Stephanopoli

INVEST SECURITIES - QIAGEN : Guidance réitérée avec un S2 plus dynamique - NEUTRE, OC 36€ (vs 37€)

Hugo Solvet

QIAGEN: Small uncertainties on ramp-up makes it challenging to aim higher than the low-end | BUY | EUR36.5 vs. EUR37.5 (+10%)

QIAGEN - BUY | EUR36.5 vs. EUR37.5 (+10%) Small uncertainties on ramp-up makes it challenging to aim higher than the low-end Buy reiterated, adjusted ests. at the low-end of guidance QuantiFERON-TB could emerge from the tunnel in Q3 QIAstat-Dx … timing of FDA approval will be key NGS: very ambitious targets that needs to be achieved

Michael Waterhouse

Morningstar | Dropping Coverage of Qiagen

We are dropping coverage of Qiagen. We provide broad coverage of more than 1,500 companies globally and periodically adjust our coverage according to investor interest and staffing configuration. We expect to reinitiate coverage of Qiagen later in the year.

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

ValuEngine Rating and Forecast Report for QGEN

Qiagen – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Macro Vision: Sector Synopsis

Investors continue to prefer the stability of the U.S. relative to emerging markets. The decline in emerging markets and their currencies suggest global risk aversion. U.S. equity markets are, by contrast, not showing any significant signs of coming unhinged as a result of this rout in emerging markets. We continue to monitor the following to assess the health of the U.S. market: • U.S. Dollar: The U.S. dollar remains the de-facto world currency and has aided the U.S. equity markets in staying a step above the malaise in global markets. However we would prefer to see stabilization in emerg...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Bottoms-up view on developed int'l, part two Big Picture: Our outlook remains neutral on the MSCI ACWI ex-U.S. index (when priced in local currency) while horizontal consolidation continues. On the other hand, we are negative on broad global ex-U.S. markets when priced in USD... see charts below. In today's report we take a bottoms-up approach to developed ex-U.S. equities, highlighting stocks that present attractive buy opportunities at current levels. Specifically we present actionable stocks within the Communications, Health Care, Manufacturing, Materials, Technology, Transportation, and U...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch